Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060489 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00060489: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00060489 is a Phase 3 study that has completed, run by AstraZeneca. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060489, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
Interventions
- DRUG SEROQUEL (quetiapine fumarate) Tablets
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
What the finished NCT00060489 record still lists
NCT00060489 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which SEROQUEL (quetiapine fumarate) Tablets is the first listed.
NCT00060489 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00060489 about?
NCT00060489 is a clinical study titled "Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression". The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
What is the current status of trial NCT00060489?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00060489?
The interventions under investigation include: SEROQUEL (quetiapine fumarate) Tablets (DRUG).
Who is sponsoring clinical trial NCT00060489?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia